The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes with neoadjuvant chemotherapy and/or osimertinib in patients with EGFR-mutant resectable non-small cell lung cancers.
 
Prashasti Agrawal
Honoraria - MJH Life Sciences
 
Julia Rotow
Honoraria - AstraZeneca; Daiichi Sankyo; Pfizer
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bioatla; BMS; Boehringer Ingelheim; Daiichi Sankyo; G1 Therapeutics; Genentech; Guardant Health; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Merus; Pfizer; Sanofi/Regeneron; Summit Therapeutics; Takeda
Research Funding - Abbvie (Inst); Altor BioScience (Inst); AstraZeneca (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); DualityBio (Inst); Enliven Therapeutics (Inst); EpimAb (Inst); ImmunityBio (Inst); Loxo (Inst); ORIC Pharmaceuticals (Inst); RedCloud Biotech (Inst); Regeneron (Inst); Summit Therapeutics (Inst); Synthekine (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Black Diamond Therapeutics; BMS; Johnson & Johnson/Janssen; Merus
 
Gaetano Rocco
Consulting or Advisory Role - Merck
Speakers' Bureau - Medtronic
Patents, Royalties, Other Intellectual Property - Scanlan
 
William Travis
Consulting or Advisory Role - Genentech
 
Eduardo Ortiz
No Relationships to Disclose
 
Rebecca Scalabrino
No Relationships to Disclose
 
Jaclyn LoPiccolo
Consulting or Advisory Role - 23andMe
 
Francesco Facchinetti
Speakers' Bureau - Roche
 
Helena Yu
Consulting or Advisory Role - Abbvie; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines; Bristol-Myers Squibb/Roche; C4 Therapeutics; Cullinan Oncology; Daiichi Sankyo; Janssen; Novocure; Orion Clinical; Taiho Oncology; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cullinan Oncology (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Janssen Oncology (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Systimmune (Inst)
Other Relationship - Astellas Pharma
 
David Jones
Consulting or Advisory Role - AstraZeneca
Research Funding - Merck
 
Jamie Chaft
Consulting or Advisory Role - Arcus Biosciences; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Guardant Health; Janssen Oncology; Lilly; Merck; Sanofi/Regeneron
Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis
(OPTIONAL) Uncompensated Relationships - AstraZeneca